Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cytokinetics (CYTK) EBITDA Margin (2016 - 2025)

Historic EBITDA Margin for Cytokinetics (CYTK) over the last 16 years, with Q4 2024 value amounting to 1711.89%.

  • Cytokinetics' EBITDA Margin rose 98477800.0% to 1711.89% in Q4 2024 from the same period last year, while for Dec 2024 it was 7943.69%, marking a year-over-year increase of 148847800.0%. This contributed to the annual value of 1557.3% for FY2024, which is 84983900.0% up from last year.
  • Per Cytokinetics' latest filing, its EBITDA Margin stood at 1711.89% for Q4 2024, which was up 98477800.0% from 33290.71% recorded in Q3 2024.
  • Cytokinetics' 5-year EBITDA Margin high stood at 1711.89% for Q4 2024, and its period low was 57751.41% during Q2 2024.
  • Its 5-year average for EBITDA Margin is 9615.92%, with a median of 2485.77% in 2021.
  • Examining YoY changes over the last 5 years, Cytokinetics' EBITDA Margin showed a top increase of 98477800bps in 2024 and a maximum decrease of -429359500bps in 2024.
  • Cytokinetics' EBITDA Margin (Quarter) stood at 354.9% in 2020, then tumbled by -122bps to 78.29% in 2021, then plummeted by -8738bps to 6919.32% in 2022, then decreased by -18bps to 8135.89% in 2023, then soared by 121bps to 1711.89% in 2024.
  • Its EBITDA Margin stands at 1711.89% for Q4 2024, versus 33290.71% for Q3 2024 and 57751.41% for Q2 2024.